Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintained a price target of $72.
October 17, 2024 | 9:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Cytokinetics and maintained a price target of $72, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $72 price target by a reputable analyst suggests a positive outlook for Cytokinetics. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100